NDA for NTM Lung Disease Treatment Submitted to FDA
Insmed Incorporated announced that it has submitted its New Drug Application for amikacin liposome inhalation suspension (ALIS) to the U.S. FDA.
Q&A with Hartmann Wellhoefer, Shire's VP and Head of Medical Affairs; Rare Diseases & Internal Medic
Hartmann Wellhoefer, M.D., head of medical affairs at Shire, recently sat down with Rare Disease Report to discuss the company's recent work for the rare disease community, particularly lysosomal storage diseases.
ORDI Rare Disease Day Campaign Off and Running with Race for 7
In an effort to raise awareness about the rare disease community, ORDI is organizing the Race for 7 run.
2 Commerce Drive Cranbury, NJ 08512